vs
Side-by-side financial comparison of Protalix BioTherapeutics, Inc. (PLX) and DNA X, Inc. (SONM). Click either name above to swap in a different company.
DNA X, Inc. is the larger business by last-quarter revenue ($16.2M vs $9.1M, roughly 1.8× Protalix BioTherapeutics, Inc.). DNA X, Inc. runs the higher net margin — -29.3% vs -60.3%, a 31.0% gap on every dollar of revenue. On growth, DNA X, Inc. posted the faster year-over-year revenue change (7.9% vs -49.9%). Over the past eight quarters, DNA X, Inc.'s revenue compounded faster (9.9% CAGR vs -6.7%).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
PLX vs SONM — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $16.2M |
| Net Profit | $-5.5M | $-4.8M |
| Gross Margin | 49.4% | 11.2% |
| Operating Margin | -51.1% | -24.5% |
| Net Margin | -60.3% | -29.3% |
| Revenue YoY | -49.9% | 7.9% |
| Net Profit YoY | -184.8% | -89.2% |
| EPS (diluted) | $-0.06 | $-4.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | — | ||
| Q3 25 | $17.9M | $16.2M | ||
| Q2 25 | $15.7M | $11.2M | ||
| Q1 25 | $10.1M | $16.7M | ||
| Q4 24 | $18.2M | $15.3M | ||
| Q3 24 | $18.0M | $15.0M | ||
| Q2 24 | $13.5M | $11.5M | ||
| Q1 24 | — | $9.1M |
| Q4 25 | $-5.5M | — | ||
| Q3 25 | $2.4M | $-4.8M | ||
| Q2 25 | $164.0K | $-7.5M | ||
| Q1 25 | $-3.6M | $458.0K | ||
| Q4 24 | $6.5M | $-21.6M | ||
| Q3 24 | $3.2M | $-2.5M | ||
| Q2 24 | $-2.2M | $-6.6M | ||
| Q1 24 | — | $-2.9M |
| Q4 25 | 49.4% | — | ||
| Q3 25 | 53.4% | 11.2% | ||
| Q2 25 | 62.5% | 7.6% | ||
| Q1 25 | 19.1% | 50.0% | ||
| Q4 24 | 78.7% | -1.2% | ||
| Q3 24 | 53.4% | 28.2% | ||
| Q2 24 | 29.8% | 25.8% | ||
| Q1 24 | — | 31.8% |
| Q4 25 | -51.1% | — | ||
| Q3 25 | 11.9% | -24.5% | ||
| Q2 25 | 7.5% | -60.2% | ||
| Q1 25 | -41.0% | 3.9% | ||
| Q4 24 | 39.6% | 55.3% | ||
| Q3 24 | 22.2% | -15.8% | ||
| Q2 24 | -18.0% | -56.2% | ||
| Q1 24 | — | -29.5% |
| Q4 25 | -60.3% | — | ||
| Q3 25 | 13.2% | -29.3% | ||
| Q2 25 | 1.0% | -66.8% | ||
| Q1 25 | -35.8% | 2.7% | ||
| Q4 24 | 35.6% | -141.6% | ||
| Q3 24 | 18.0% | -16.7% | ||
| Q2 24 | -16.4% | -57.5% | ||
| Q1 24 | — | -31.9% |
| Q4 25 | $-0.06 | — | ||
| Q3 25 | $0.03 | $-4.83 | ||
| Q2 25 | $0.00 | $-0.79 | ||
| Q1 25 | $-0.05 | $0.08 | ||
| Q4 24 | $0.10 | $-116.99 | ||
| Q3 24 | $0.03 | $-9.32 | ||
| Q2 24 | $-0.03 | $-1.41 | ||
| Q1 24 | — | $-0.65 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.7M | $2.1M |
| Total DebtLower is stronger | — | $5.1M |
| Stockholders' EquityBook value | $48.2M | $-701.0K |
| Total Assets | $82.3M | $40.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.7M | — | ||
| Q3 25 | $13.6M | $2.1M | ||
| Q2 25 | $17.9M | $2.0M | ||
| Q1 25 | $19.5M | $2.1M | ||
| Q4 24 | $19.8M | $5.3M | ||
| Q3 24 | $27.4M | $9.1M | ||
| Q2 24 | $23.4M | $9.6M | ||
| Q1 24 | — | $9.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | $5.1M | ||
| Q2 25 | — | $2.9M | ||
| Q1 25 | — | $2.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $48.2M | — | ||
| Q3 25 | $52.9M | $-701.0K | ||
| Q2 25 | $49.9M | $-1.3M | ||
| Q1 25 | $45.2M | $-1.1M | ||
| Q4 24 | $43.2M | $-5.7M | ||
| Q3 24 | $32.4M | $15.3M | ||
| Q2 24 | $28.6M | $17.5M | ||
| Q1 24 | — | $19.8M |
| Q4 25 | $82.3M | — | ||
| Q3 25 | $82.3M | $40.2M | ||
| Q2 25 | $78.5M | $36.1M | ||
| Q1 25 | $73.9M | $36.0M | ||
| Q4 24 | $73.4M | $39.7M | ||
| Q3 24 | $61.6M | $49.1M | ||
| Q2 24 | $91.5M | $45.9M | ||
| Q1 24 | — | $42.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $-7.0M |
| Free Cash FlowOCF − Capex | $1.6M | — |
| FCF MarginFCF / Revenue | 17.8% | — |
| Capex IntensityCapex / Revenue | 4.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-13.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | — | ||
| Q3 25 | $-3.7M | $-7.0M | ||
| Q2 25 | $-5.2M | $-4.9M | ||
| Q1 25 | $-5.1M | $-9.6M | ||
| Q4 24 | $4.0M | $-4.5M | ||
| Q3 24 | $4.1M | $-417.0K | ||
| Q2 24 | $-3.6M | $-3.4M | ||
| Q1 24 | — | $-168.0K |
| Q4 25 | $1.6M | — | ||
| Q3 25 | $-4.2M | — | ||
| Q2 25 | $-5.7M | — | ||
| Q1 25 | $-5.4M | — | ||
| Q4 24 | $3.6M | $-4.5M | ||
| Q3 24 | $4.0M | $-554.0K | ||
| Q2 24 | $-3.8M | $-3.4M | ||
| Q1 24 | — | $-198.0K |
| Q4 25 | 17.8% | — | ||
| Q3 25 | -23.7% | — | ||
| Q2 25 | -36.2% | — | ||
| Q1 25 | -53.0% | — | ||
| Q4 24 | 19.6% | -29.6% | ||
| Q3 24 | 22.4% | -3.7% | ||
| Q2 24 | -28.1% | -29.8% | ||
| Q1 24 | — | -2.2% |
| Q4 25 | 4.4% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 2.8% | — | ||
| Q1 25 | 3.0% | — | ||
| Q4 24 | 2.3% | 0.1% | ||
| Q3 24 | 0.5% | 0.9% | ||
| Q2 24 | 1.3% | 0.3% | ||
| Q1 24 | — | 0.3% |
| Q4 25 | — | — | ||
| Q3 25 | -1.58× | — | ||
| Q2 25 | -31.91× | — | ||
| Q1 25 | — | -20.97× | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
SONM
Segment breakdown not available.
